Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Risueño

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Plos One|December 17, 2008
Human gene coexpression landscape: confident network derived from tissue transcriptomic profilesCarlos Prieto, Alberto Risueño, Celia Fontanillo, et al.
BMC Bioinformatics|May 1, 2010
GATExplorer: genomic and transcriptomic explorer; mapping expression probes to gene loci, transcripts, exons and ncRNAsAlberto Risueño, Celia Fontanillo, Marcel E Dinger, et al.
BMC Genomics|October 10, 2014
A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samplesAlberto Risueño, Beatriz Roson-Burgo, Anna Dolnik, et al.
American Journal of Hematology|October 2, 2023
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemiaMaciej W Garbowski, Manuel Ugidos, Alberto Risueño, et al.
Biomed Research International|April 3, 2014
TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variationsMaría Hernández-Sánchez, Ana Eugenia Rodríguez, Alexander Kohlmann, et al.
British Journal of Haematology|March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trialDaniel L Menezes, Wendy L See, Alberto Risueño, et al.
Leukemia Research|April 2, 2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AMLAlberto Risueño, Wendy L See, Iryna Bluemmert, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
American Journal of Hematology|January 19, 2023
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trialAndrew H Wei, Hartmut Döhner, Hamid Sayar, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Plos One|December 17, 2008
Human gene coexpression landscape: confident network derived from tissue transcriptomic profilesCarlos Prieto, Alberto Risueño, Celia Fontanillo, et al.
BMC Bioinformatics|May 1, 2010
GATExplorer: genomic and transcriptomic explorer; mapping expression probes to gene loci, transcripts, exons and ncRNAsAlberto Risueño, Celia Fontanillo, Marcel E Dinger, et al.
BMC Genomics|October 10, 2014
A robust estimation of exon expression to identify alternative spliced genes applied to human tissues and cancer samplesAlberto Risueño, Beatriz Roson-Burgo, Anna Dolnik, et al.
American Journal of Hematology|October 2, 2023
Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemiaMaciej W Garbowski, Manuel Ugidos, Alberto Risueño, et al.
Biomed Research International|April 3, 2014
TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variationsMaría Hernández-Sánchez, Ana Eugenia Rodríguez, Alexander Kohlmann, et al.
British Journal of Haematology|March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trialDaniel L Menezes, Wendy L See, Alberto Risueño, et al.
Leukemia Research|April 2, 2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AMLAlberto Risueño, Wendy L See, Iryna Bluemmert, et al.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
American Journal of Hematology|January 19, 2023
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trialAndrew H Wei, Hartmut Döhner, Hamid Sayar, et al.
Pageof 2